Related Experiment Video

Updated: Dec 30, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Multikinase Inhibitor Crizotinib Is Active in MET Exon 14-Altered Lung Cancer

    Cancer Discovery
    |January 26, 2020
    PubMed

    Insights

    Crizotinib effectively treats non-small cell lung cancer (NSCLC) harboring specific MET exon 14 alterations. This targeted therapy offers a new option for patients with this genetic mutation.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Non-small cell lung cancer (NSCLC) is a leading cause of cancer death.
    • Genetic alterations, such as in MET exon 14, drive tumor growth in a subset of NSCLC patients.
    • Targeted therapies are crucial for improving outcomes in NSCLC.

    Purpose of the Study:

    • To evaluate the efficacy of crizotinib in patients with NSCLC.
    • To investigate the role of MET exon 14 alterations in treatment response.

    Main Methods:

    • Clinical trial data analysis.
    • Molecular profiling of NSCLC tumors.
    • Assessment of treatment response to crizotinib.

    Main Results:

    • Crizotinib demonstrated significant efficacy in patients with NSCLC.
    • Patients with MET exon 14 alterations showed a positive response to crizotinib treatment.
    • Durable responses were observed in the treated patient cohort.

    Conclusions:

    • Crizotinib is an effective treatment option for non-small cell lung cancer (NSCLC) with MET exon 14 alterations.
    • Targeting MET exon 14 mutations with crizotinib represents a promising therapeutic strategy.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.1K
    Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing09:49

    Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

    Published on: July 5, 2019

    9.9K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.6K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    5.5K